NCT01897701View on ClinicalTrials.gov

A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1

PHASE1CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Avian Influenza
Interventions
BIOLOGICAL

Monovalent Avian Influenza VLP (H7N9)

BIOLOGICAL

Adjuvant 1

BIOLOGICAL

Placebo

Trial Locations (3)

4006

Q-Pharm Pty Limited, Herston

5000

CMAX, Adelaide

6009

Linear Clinical Research, Nedlands

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY

NCT01897701 - A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 | Biotech Hunter | Biotech Hunter